Overview

Study of Safety and of the Mechanism of BLZ945 in ALS Patients

Status:
Recruiting
Trial end date:
2022-08-03
Target enrollment:
Participant gender:
Summary
It is an open label study to evaluate safety, tolerability and brain microglia response in participants with ALS following multiple doses of BLZ945.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals